nrt chart, page-4

Brokeandbusted,

I agree with you there. The company is very tight lipped and even commented at the recent AGM that they are holding back from raving about their compounds before the trials are finished.

Looking at their actions show's exactly how confident they are. An example is holding out till the end of Phase II trials before looking for a license deal. It's worked with NV-07a with that compound pretty much proven (almost finished the human trials) and almost ready to hit the market.

Oppenheimer have stocked up on NRT shares and I also notice another Kelly on the top 20. Note that the company founder Dr Kelly owns about 10% of the company and now we see another Kelly pop up with a first name same as Dr Kelly's middle name... perhaps a relative?

Anyhow, I'm confident Novogen are acting in the best interest of shareholders. Quietly doing the job, finish the trials and then start raving about the drug.

Also note that Novogen recently presented NV-07a (their anti-ageing cream) at two conferences.

1) http://www.smi-online.co.uk/_media/docs/event_J55.pdf

2) http://www.smi-online.co.uk/_media/docs/j13.pdf